Cordeel contributes to PanTera’s state-of-the-art Actinium Production Center in Mol
The APC will be a leading facility for the production of Actinium-225 (Ac-225), a highly promising radioisotope used in targeted alpha therapy for cancer treatment. Construction follows the approval of all nuclear and environmental permits earlier this year.
Proud of our role in a groundbreaking medical project
At Cordeel, we are especially proud to be working with our TM WISICO partners on building an infrastructure that is not only technologically cutting-edge but also has enormous societal impact. The facility will host PanTera’s unique production process, in which radium-226 (Ra-226) is irradiated with a high-energy gamma beam to produce Ac-225. The building designs were developed by Tractebel and MODULO architects.
Operations are scheduled to start in 2028, with the first commercial supply of Ac-225 planned for 2029. Once fully operational, the site will be capable of producing hundreds of curies of Ac-225 annually. This will establish Belgium as a global player in nuclear medicine and ensure a sustainable supply of this crucial isotope for pharmaceutical companies and patients worldwide.
Belgium as a pioneer in nuclear medicine
With the construction of the Actinium Production Center, PanTera underlines its ambition to play a key role in the future production and distribution of medical isotopes. The launch of this project marks an important step forward for both the medical community and the Belgian technology sector.
For Cordeel, this project is a prime example of how we apply our expertise to innovative and socially relevant infrastructure projects. We look forward to successfully delivering this project together with our partners.